GENEVA, July 11 /PRNewswire/ -- Inspiration Biopharmaceuticals today announced the presentation of preclinical data supporting the development of new, proprietary forms of recombinant Factor IX to treat patients with Hemophilia B. The data were highlighted in an oral presentation and a poster session at the XXIst Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Geneva, Switzerland.
Dougald M. Monroe, Ph.D., Associate Professor, UNC School of Medicine, University of North Carolina at Chapel Hill, gave an oral presentation titled, “Glycosylation of the Activation Peptide of Factor IX Determines Plasma Half Life.” Michael Griffith, Ph.D., President and CEO of Inspiration Biopharmaceuticals, presented a poster titled, “N-Glycan Sialylation is Important for In Vivo Recovery of Recombinant Factor IX.” According to both presentations, Inspiration has identified structural properties of Factor IX that may improve the half-life and recovery compared to commercially available recombinant Factor IX. The company is currently refining its cGMP manufacturing process to maximize the biological properties of its clinical product based on these studies.
“Inspiration Biopharmaceuticals is seeking to revolutionize the treatment of hemophilia by providing high quality, less costly Factor products. Our ultimate goal is to increase accessibility to prophylactic treatment and improve the quality of life for people suffering from hemophilia,” said Michael Griffith, Ph.D., President and CEO, Inspiration Biopharmaceuticals. “We are therefore excited about the progress that we have made in advancing our protein manufacturing technology. We look forward to initiating clinical trials this year.”
About Recombinant Protein Manufacturing Technology
Inspiration Biopharmaceuticals uses novel patent protected, recombinant protein manufacturing technologies which are demonstrated to significantly increase cell-line productivity. This in turn decreases manufacturing capacity requirements, and significantly lowers the overall production cost for Factor products compared with existing manufacturing processes. Inspiration believes that its technologies will allow introduction of patient friendly, cost-effective products which will provide equal or enhanced potency compared to those currently available.
About Inspiration Biopharmaceuticals
Founded in 2004, Inspiration Biopharmaceuticals is focused on revolutionizing the treatment of hemophilia through production of lower cost versions of existing intravenous recombinant therapies and development of non-invasive applications to enhance prophylactic administration. The Company’s first product candidate is to be a less costly intravenous presentation of recombinant Factor IX. The proposed second generation product is a non-injectable recombinant Factor IX, designed specifically for prophylactic therapy.
Inspiration Biopharmaceuticals
CONTACT: Alison Arter of Inspiration Biopharmaceuticals,aarter@inspirationbio.com, or Media, Justin Jackson, or Kathy Nugent, orInvestors, Clay Kramer, all of Burns McClellan for InspirationBiopharmaceuticals, +1-212-213-0006